tsn

Study Reveals Insights and Concerns in COVID-19 mRNA Vaccine Safety—Serious Clusters in Vulnerable Groups

 40
1 comment
Staff at TrialSite | Quality Journalism
Feb. 9, 2025, 8:00 p.m.

A new study published in Frontiers in Medicine examines real-world safety data for Moderna's Spikevax and Pfizer/BioNTech's Comirnaty COVID-19 vaccines, utilizing nearly 1 million individual case safety reports (ICSR) from the European pharmacovigilance database, EudraVigilance. The research, conducted by a team from the University of Porto, highlights the overall safety of these vaccines while identifying significant patterns in adverse events that warrant further scrutiny.

The analysis reviewed reports from January 2020 to December 2023, documenting over 3.5 million adverse event occurrences. Most reports originated from women (69%) and non-healthcare professionals (65%), with a notable variety of 10,804 distinct adverse event terms reported. Commonly observed adverse events included headache, fatigue, pyrexia (fever), myalgia, arthralgia, nausea, and chills, often clustering with vaccine failure reports.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month 
which is less than a Starbucks coffee!

Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News